All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
David R. Nelson(University of Florida), Khurram Rana(Inova Fairfax Hospital), Eric Hughes(The University of Texas at San Antonio Health Science Center), Delphine Hennicken(Inova Fairfax Hospital), Norman Gitlin(Atlanta Gastroenterology Associates), Ziad Younes(Gastro One (United States)), Aasim Sheikh(GI Specialists of Georgia (United States)), Trevor Hawkins(University of Florida), Michael Bennett(Associates Research), Paul J. Pockros(Scripps Clinic), Paul J. Thuluvath(Inova Fairfax Hospital), Bradley Freilich(Kansas City Research Institute), Godson Oguchi(University of Florida), Eric Lawitz(The University of Texas at San Antonio Health Science Center), Peter Varunok(Inova Fairfax Hospital), Grisell Ortiz‐Lasanta(University of Florida), Natarajan Ravendhran(University of Florida), Mordechai Rabinovitz(The University of Texas at San Antonio Health Science Center), Reem Ghalib(Clinical Research Institute), Fiona McPhee(Bristol-Myers Squibb (United States)), Kris V. Kowdley(Washington State University Spokane), James N. Cooper(Inova Fairfax Hospital), David Bernstein(University of Florida), Jacob Lalezari(Quest Clinical Research (United States)), William R. Harlan(Asheville Cardiology Associates)
Cited by 689
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k